{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T23:42:00Z","timestamp":1680133320438},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1055\/a-1873-4753","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T23:18:58Z","timestamp":1680131938000},"page":"451-458","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapieoptionen bei der Akuten Myeloischen Leuk\u00e4mie"],"prefix":"10.1055","volume":"148","author":[{"given":"Miriam Helena Eva","family":"Gediga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3\n          Mutation","volume":"377","author":"RM Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"ref2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated\n          AML","volume":"381","author":"AE Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"ref3","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional\n          Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute\n          Myeloid Leukemia","volume":"36","author":"JE Lancet","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"07","key":"ref4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid\n          Leukemia","volume":"383","author":"CD DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an\n          international expert panel on behalf of the ELN","volume":"140","author":"H D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly\n          diagnosed acute myeloid leukemia?","volume":"136","author":"C R\u00f6llig","year":"2020","journal-title":"Blood"},{"issue":"26","key":"ref8","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for\n          Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"A Burchert","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing\n          allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre,\n          randomised phase 3 trial","volume":"21","author":"L Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"ref10","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First\n          Remission","volume":"383","author":"AH Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"S DeWolf","year":"2020","journal-title":"Blood"},{"issue":"10","key":"ref12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning\n          following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"D Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/moh.0b013e3283366bb8","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans\n          retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in\n          patients not considered fit for intensive treatment","volume":"109","author":"AK Burnett","year":"2007","journal-title":"Cancer"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient\n          choice, with physician advice, of either supportive care or low-dose cytarabine for the\n          treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"HM Kantarjian","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older\n          patients with newly diagnosed AML with >30% blasts","volume":"126","author":"H Dombret","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and\n          safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"J Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute\n          myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"S Castaigne","year":"2012","journal-title":"Lancet Lond Engl"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the\n          Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial","volume":"29","author":"AK Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with\n          acute myeloid leukaemia: a meta-analysis of individual patient data from randomised\n          controlled trials","volume":"15","author":"RK Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From\n          the Prospective Randomized AMLSG 09\u201309 Phase III Study","volume":"38","author":"RF Schlenk","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"ref21","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with\n          NPM1-mutated AML: results from the AMLSG 09\u201309 trial","volume":"136","author":"S Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"08","key":"ref22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and\n          daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute\n          myeloid leukemia","volume":"29","author":"EJ Feldman","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"07","key":"ref23","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with\n          newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a\n          randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"JE Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"07","key":"ref24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed\n          IDH1-mutant acute myeloid leukemia","volume":"135","author":"GJ Roboz","year":"2020","journal-title":"Blood"},{"issue":"25","key":"ref25","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory\n          AML","volume":"378","author":"CD DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"P Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"06","key":"ref27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"EM Stein","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients\n          with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic\n          syndrome","volume":"33","author":"JE Cortes","year":"2019","journal-title":"Leukemia"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1873-4753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T23:19:58Z","timestamp":1680131998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1873-4753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":27,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2023,3,29]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1873-4753","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}